Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RSV
Biotech
Pfizer axes another RSV med picked up in $525M ReViral buy
In another blow to its $525 million ReViral buy, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV.
Gabrielle Masson
Oct 8, 2024 4:58pm
Enanta's RSV antiviral crushes viral load in challenge study
Sep 26, 2024 7:43am
Vicebio hauls in $100M series B to push RSV shot through phase 1
Sep 23, 2024 3:00am
Pfizer takes $230M hit after axing failed DMD gene therapy
Jul 30, 2024 8:15am
FDA delays decision on Moderna's RSV shot until the end of May
May 10, 2024 10:30am
Layoffs at Meissa Vaccines as biotech's future lies in limbo
Mar 5, 2024 10:25am
